ClinicalTrials.gg
RecruitingNCT04781322Updated Jul 20, 2026

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

A Phase 1 interventional study of Alirocumab and Placebo in Alcohol Associated Liver Disease and Heavy Drinking Behavior, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA). Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
52nd of 163
100 · median 44
Started
2021
with 11 others
Phase 1
19 of 212
4 open now
Primary completion
2026-12
later than 10 of 47 live
Registered
146th of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 52nd largest by planned enrollment of the 163 interventional ones that give a count, is one of 12 that started in 2021, is one of 19 in phase 1, reaches primary completion later than 10 of the 47 other live ones, and was the 146th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

Background:

Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning/swelling.

Objective:

To study the effects of alirocumab in people who drink alcohol.

Eligibility:

Healthy adults ages 21 to 65 who regularly consume an average of 20 or more drinks per week.

Design:

Participants will be screened under protocol 14-AA-0181.

Participants will get alirocumab or a placebo as an injection under the skin.

Participants will give blood and urine samples. They will have physical exams.

Participants will have FibroScans . It measures liver and spleen stiffness. Participants will lie on a table. They will expose the lower right and left side of their chest. The machine will send a small vibration to the liver.

Participants may have magnetic resonance imaging (MRI) scans of the liver. The MRI scanner is shaped like a cylinder. Participants will lie on a table that slides in and out of the scanner. A device called a coil will be placed over their liver.

Participants will have a Doppler scan and ultrasound. These tests measure blood flow in the body.

Participants will have an electrocardiogram. It measures heart function.

Participants will fill out surveys about how they are feeling, their alcohol consumption, and other behaviors. They will complete cognitive tasks on a computer.

Participants will meet with a clinician. They will discuss the participant s assessment results, patterns of drinking, and possibly stopping or cutting down on drinking.

Participation will last for 8 weeks. Participants will have 9 study visits.

Read the detailed description

Study Description:

The PCSK9 inhibitor alirocumab has been recently shown to attenuate alcohol-induced hepatic triglyceride accumulation, hepatocellular injury and hepatic inflammation in a rat model of chronic alcohol exposure. Given the unmet clinical need for novel treatment options for alcohol-associated liver disease (ALD), we are proposing to conduct a safety and tolerability study of alirocumab in this new target population.

We hypothesize that alirocumab will be well tolerated and safe in this new target population and alirocumab will attenuate alcohol-induced liver damage and inflammatory biomarkers.

Objectives:

Primary Objective: The primary objective is to assess the safety and tolerability of alirocumab in subjects who are heavy drinkers.

Secondary/Exploratory Objectives: Secondary/exploratory objectives are to assess various biomarkers related to alcohol-induced liver damage and inflammation.

Endpoints:

Primary Endpoint: The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in non-treatment seeking heavy drinkers treated with alirocumab or placebo. [Time Frame: baseline to week 8]

Secondary/exploratory Endpoints: The secondary endpoint is to explore effects of alirocumab on various biomarkers using change from baseline.

03

Conditions studied

  • Alcohol Associated Liver Disease
  • Heavy Drinking Behavior

Keywords

  • Alcohol
  • Liver
  • PCSK9
  • Fatty Liver
  • Inflammation
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between the age of 21 and 65 years.

    1. Ability to provide written .
    2. Females: Negative urine pregnancy test, not currently breastfeeding, agree to abstain or use accepted form of including use of oral contraceptives; use of barrier method of contraceptive, such as condoms; use of an approved IUD or other long-acting reversible contraceptive (LARC); have a male sexual partner who is surgically sterilized; or have exclusively female sexual partner(s).

      Males: Agree to abstain or use accepted form of contraception, such as condoms.

    3. Current chronic alcohol use, non-treatment seeking heavy drinker (an average of >= 20 standard drinks per week for at least 12 weeks).

Exclusion criteria

EXCLUSION CRITERIA:

  1. Treatment seeking for alcohol use disorder.
  2. History of a serious reaction to PCSK9 inhibitors, monoclonal antibodies, or any component of the drug product.
  3. Chronic use of statins within eight weeks of the study to treat hypercholesteremia, or fibrates, with the exception of fenofibrates, within six weeks of the study.
  4. Current/past use of PCSK9 inhibitors.
  5. and/or unstable cardiovascular-disease over the past 12 months.
  6. Current or prior history of any clinically significant disease, including, fibromyalgia, severe neuropathic pain, seizure disorder, uncontrolled endocrine disease known to influence serum lipids or lipoproteins, hemorrhagic stroke, cancer within the past 5 years (except for adequately treated basal skin cancer, squamous cell skin cancer, or in situ cervical cancer), uncontrolled (defined as A1c >8%) or newly diagnosed (within 3 months prior to screening) diabetes, or any other significant abnormality identified at the time of screening that, in the judgment of the investigator or study clinician, would preclude safe completion of the study.
  7. Positive test or positive surface antigen (HBsAg), and/or positive antibody (HCV) at screening.
  8. or aspartate aminotransferase exceeding 5 times the levels at screening will be excluded. 2x UNL or Creatinine > 1.5 mg/dl at screening will be excluded.
  9. Triglycerides > 400mg/dL (>4.52 mmol/L) at screening.
  10. Chronic renal failure as estimated by (GFR) \< 60mL/min/1.73 m\^2 at screening.
  11. Any underlying clinically significant and/or unstable acute or chronic liver disease unrelated to alcohol use at screening.
  12. Patients with coagulopathy defined as >1.5, prothrombin time prolonged by > 3s, and/or \<75,000 / mm\^3 at screening.
  13. Use of any medications that interfere with blood clotting.
  14. Patients with significant hematologic abnormalities.
  15. Significant obesity (Obesity Class III) defined as greater than or equal to 40 at screening.
  16. History of previous bariatric surgery or transplant surgery.
  17. History of plasmapheresis treatment within 2 months prior to screening or plans to undergo plasmapheresis during the study.
  18. Use of the following medications: Any medication that requires intramuscular administration injections. Systemic , unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to screening. Estrogen or testosterone therapy, unless regimen stable for 6 weeks prior to screening visit.
  19. Use of any drugs within 1 month, or five half-lives, whichever is longer, of the study procedures.
  20. Plan to use red yeast rice during the study.
  21. Presence of any current suicidality.
  22. History of epilepsy or alcohol-related seizures in the last 12 months.
  23. Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study, such as psychosis, delirium or acute change of mental status.

For optional MRI: a) Presence of ferromagnetic objects in the body that may be adversely affected by or for MRI, fear of enclosed spaces, or other standard contraindication to MRI, as determined by self-report b) Use of MRI-incompatible intrauterine device (IUD).

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention

    Heavy drinking healthy volunteers

    Drug: Alirocumab

  • Placebo comparator
    Placebo

    Heavy drinking healthy volunteers

    Other: Placebo

Interventions

  • Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.

  • OtherPlacebo

    Heavy drinking healthy volunteers

06

What researchers measure

Primary outcomes

  1. The primary objective is to assess the safety and tolerability of alirocumab in subjects who are heavy drinkers.

    The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in non-treatment seeking heavy drinkers treated with alirocumab or placebo.

    Time frame: 8 weeks

Secondary outcomes

  1. Secondary/exploratory objectives are to assess various biomarkers related to alcohol-induced liver damage and inflammation.

    These biomarkers will assess various biological processed in AUD, such as inflammation, liver biology and clinical alcohol-related outcomes.

    Time frame: ongoing

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactprpl@cc.nih.gov · 800-411-1222
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 4, 2021
StartActual
Oct 19, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04781322
Responsible party
Sponsor
First posted
Mar 4, 2021
Start date
Oct 19, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 20, 2026

Study contacts

Nada M Saleh
Contact
nada.saleh@nih.gov
(301) 496-3799
Falk W Lohoff, M.D.
Contact
falk.lohoff@nih.gov
(301) 827-1542
Falk W Lohoff, M.D.
principal investigator · National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion